Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050117 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL415693 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL6050257 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL1128201 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL4714660 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL2094922 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL416692 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL6050352 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL1127858 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL416603 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-2101822-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-23 | — | — | EP | claimed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | claimed |
| WO-2008087190-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | claimed |
| EP-2283037-A1 | PROCESS | Novo Nordisk A/S (DK) | 2011-02-16 | — | — | EP | disclosed |
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| WO-2009141392-A1 | PROCESS | NOVO NORDISK A/S (DK) | 2009-11-26 | — | — | WO | disclosed |
| EP-2101822-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-23 | — | — | EP | disclosed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| WO-2008087190-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | MC4R, GIPR, MC3R | L3MBTL1 2467/4885 |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | L3MBTL1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.